RASSF2 and neoplasm: We also assessed RASSF2-mediated tumor suppression in vivo using a murine retroviral transduction and transplantation model of t(8;21) AML with the alternatively spliced leukemogenic protein variant, RUNX1-ETO9a (RE9a, Fig. 3d)40.